Prognostic value of 8q gain in relation to BAP1 and SF3B1 mutated uveal melanoma

Josephine Q.N. Nguyen, MD^{1,2}, Wojtek Drabarek, MD³, Jolanda Vaarwater, BS^{1,2}, Serdar Yavuzyigitoglu, MD, PhD¹, Robert M. Verdijk, MD, PhD^{4,5}, Dion Paridaens, MD, PhD^{1,3}, Nicole C. Naus, MD, PhD¹, Annelies de Klein, PhD², Erwin Brosens, PhD^{2,7} and Emine Kiliç, MD, PhD^{1,7} on behalf of the Rotterdam Ocular Melanoma Study group

¹ Department of Ophthalmology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.

² Department of Clinical Genetics, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.

³ The Rotterdam Eye Hospital, 3011 BH, Rotterdam, The Netherlands.

⁴ Department of Pathology, Section Ophthalmic Pathology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.

⁵ Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

⁶ The Rotterdam Eye Hospital, 3011 BH, Rotterdam, The Netherlands.

⁷ These authors contributed equally to this work. Correspondence: <u>e.brosens@erasmusmc.nl</u>, <u>e.kilic@erasmusmc.nl</u>

The Rotterdam Ocular Melanoma Study Group (ROMS) is a collaborative research group with

members from the Rotterdam Eye Hospital, Departments of Ophthalmology, Pathology and Clinical

Genetics, of the Erasmus MC, Rotterdam, The Netherlands.

Financial support: This study was funded by the Henkes foundation (2021-04), Rotterdam, The Netherlands and the Combined Ophthalmic Research Rotterdam (6.2.0), Rotterdam The Netherlands. The funding organizations had no role in the design or conduct of this research.

Conflict of interest: no conflicting relationship exists for any author.

Address for reprints: Emine Kilic, Department of Ophthalmology, room Ee1610, Erasmus MC Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands

Unstructured abstract: Chromosome 8q gain is associated with poor prognosis. Here, we show that the predictive value of chromosome 8q gain depends on the mutation status and is true for *BAP1* but not for *SF3B1*-mutated tumors.

1 Uveal melanoma (UM) is the most common primary intraocular malignancy in adults [1]. 2 Recurrent mutations in secondary driver genes BAP1, SF3B1, and EIF1AX, as well as characteristic 3 copy number variations (CNV) and gene expression profiles (GEP) are used in prognostication. Previously, gain of chromosome 8g has been associated with poor prognosis, with increased 4 numbers of 8q correlating with shorter survival [2]. Whereas in BAP1-mutated (BAP1^{MUT}) UM. gain of 5 8q is the result of whole chromosome 8 gain or the formation of isochromosome 8q, in case of 6 *SF3B1*-mutated (*SF3B1^{MUT}*) UM structural, often partial gain of 8g is predominant [3]. Some of these 7 SF3B1^{MUT} UM patients develop early-onset metastatic disease [4], prompting to investigate the 8 relationship between survival, gain of 8q and SF3B1^{MUT} UM. 9

Patients with *SF3B1*^{MUT} tumors (n=59) from the Rotterdam Ocular Melanoma Study group 10 diagnosed between 1994 and 2022 were included in this study. CNVs were assessed using single 11 12 nucleotide polymorphism (SNP) array (n=55) or in the past with karyotyping (n=17) and or 13 fluorescence in situ hybridization (FISH, n=28) and when material was available used for 14 transcriptome profiling (n=19) [4]. The summary plot showing the chromosomal patterns of the SNP 15 arrays can be found in the supplementary (available at www.aaojournals.org). Disease-free survival 16 (DFS) was determined using a cut-off of 60 months to identify early-onset metastatic disease in UM 17 patients [4].

18 Gain of chromosome 8q was present in 48 tumors (81%) (Figure 1a). Cox proportional hazard 19 analysis could not confirm reported independent [2] prognostic value of gain of 8g in general (>2 copies) in SF3B1^{MUT} UM (HR: 1.042 (95%;CI:0.3105-4.733)), nor the number of additional 8q copies (3 20 21 copies of 8g, HR: 1.213 (95%;CI:0.3363-5.736); ≥4 copies of 8g, HR: 0.6913 (95%;CI:0.08939-4.264)) in SF3B1^{MUT} tumors. Kaplan-Meier survival analysis also indicated no difference in survival in patients 22 with or without 8q gain (p=0.9854; Figure 1b) nor is there a difference between 2, 3 or \geq 4 copies 23 (p=0.6927; Figure 1d). However, since 8q gain is a characteristic of SF3B1^{MUT} as well as BAP1^{MUT} 24 25 tumors, the prognostic value of 8g gain could also be only attributed to BAP1^{MUT} tumors. Therefore, 26 we assessed the survival of 211 UM patients with immunohistochemically BAP1-negative tumors or 27 tumors with BAP1 mutations. Gain of chromosome 8q was present in 181 tumors (86%) and this was correlated with a worse survival in BAP1^{MUT} UM (p=0.0134; Figure 1c). Three copies of 8g was not 28 29 associated with decreased survival (HR: 1.667 (95%;CI:0.9755-3.042) but more copies (\geq 4 copies) 30 had predictive value (HR: 1.907 (95%;CI:1.103-3.507, Figure 1e). Since (partial) gain of 8q can also be accompanied with changes in 8p copy number, 8p status in SF3B1^{MUT} tumors was also assessed in 8g 31 gain tumors (1 copy 8p (2.1%); 2 copies 8p (77.1%); ≥3 copies 8p (20.8%)) (Figure 1a). Next, the 32 survival plot was stratified on 8p status. Patients with a SF3B1^{MUT} tumor and loss or gain of 8p (1 33 copy 8p, n=1; 3 copies 8q, n=4) in combination with 3 copies of 8q had the shortest survival 34

(p=0.0352). Since BAP1^{MUT} tumors have recurrent isochromosome 8g, we explored the combination 35 36 of 8q and 8p status, where 8q gain was accompanied with 1 copy (40%), 2 copies (35%) and \geq 3 copies of 8p (25%). However, no difference was found in 8p status between SF3B1^{MUT} and BAP1^{MUT} 37 38 tumors (p=0.4149). Nonetheless, many aberrations can be overlooked with single probe detection. 39 No difference was found in copies of 8p (p=0.2274) and 8g (p=0.8237) between DFS<60 months (n=8) and DFS≥60 months (n=51) in SF3B1^{MUT} tumors (Figure 1a). Distal gains (8q23-8q24.3) were 40 similar in patients with a DFS<60 months and DFS≥60 months (71% vs 78%; p=0.7122), more 41 42 proximal (8q1-8q23) gains were more prominent in DFS<60 patients, though this difference was not 43 significant (71% vs 41%; p=0.1461). Fifteen patients have metastatic disease (DFS<60 months, n=8 (88% 8q gain); DFS≥60 months, n=7 (71.4% 8q gain)) [4]. When grouping patients based on DFS, the 44 45 number of 8q copies was not associated with survival (DFS<60, p=0.5319; DFS \geq 60, p=0.2328) (Figure 46 1f-g). Interestingly, ≥ 4 copies of 8q corresponded to the best survival (100%) in patients with DFS ≥ 60 months. Of the patients with DFS \geq 60 months and \geq 4 copies of 8q, 50% had \geq 3 copies of 8p, whereas 47 48 25% of the patients with DFS<60 months and \geq 4 copies of 8g had \geq 3 copies of 8p. Transcriptome profiling and evaluating the genes from the GEP test on SF3B1^{MUT} (n=12) and BAP1^{MUT} (n=7) tumors 49 50 showed no discriminating factor with 8g status (p=0.4149). One of the genes distinguishing DFS<60 51 and DFS≥60, TOP1MT [4] is located at 8q24.3 and did not cluster to any group (Figure 1h).

SF3B1^{MUT} and BAP1^{MUT} tumors often have (partial) 8g gain [3, 5]. Gain of 8g is correlated to 52 prognosis in UM, with increased metastatic risk correlates with increased 8q copy numbers, often a 53 54 result of isochromosome formation [2, 5]. Here, we show that 8g gain has no discriminating association with survival in early versus late metastasizing SF3B1^{MUT} tumors. Nevertheless, gain of 8q 55 could still play a role in metastases in SF3B1^{MUT} tumors, independent of DFS. BAP1^{MUT} tumors 56 contribute to >50% of all UM and are characterized by gains and losses of entire chromosomes or 57 58 chromosome arms. Gain of 8g is often accompanied with monosomy 3, and its combination correlates with a worse prognosis [6, 7]. In contrast, SF3B1^{MUT} UM karyotypes are more complex and 59 60 CNV often have recurrent distal breakpoints on chromosome 6 and 8. This difference in CNV 61 patterns could indicate a separate tumorigenesis mechanism in both groups. Since 8q gain was correlated with survival in only BAP1^{MUT} tumors and not SF3B1^{MUT} tumors, the reported decreased 62 survival in 8g gain is predominantly due to BAP1^{MUT} tumors. 63

To conclude, we have evaluated gain of chromosome 8q and its role on DFS in *SF3B1*^{MUT} and *BAP1*^{MUT} UM. There is no correlation between 8q gain and early-onset metastasis in *SF3B1*^{MUT} tumors. Gain of 8q has no additional predictive value in *SF3B1*^{MUT} tumors. In contrast, 8q gain is predictive for a worse prognosis in *BAP1*^{MUT} tumors. Thus, 8q gain has additional predictive value for *BAP1*^{MUT} tumors, but not for *SF3B1*^{MUT} tumors.



69

Figure 1. Frequency of 8p and 8q copies in (a) all $SF3B1^{MUT}$ tumors, 8q gain $SF3B1^{MUT}$ tumors, and early (< 60 months) vs late (\geq 60 months) DFS; chromosome 8q status in (b) $SF3B1^{MUT}$ tumors and (c) $BAP1^{MUT}$ tumors; chromosome 8q copy numbers in (d) $SF3B1^{MUT}$ tumors and (e) $BAP1^{MUT}$ tumors; chromosome 8q copy numbers in (f) early and (g) late DFS $SF3B1^{MUT}$ tumors; (h) heatmap using Z-scores of the GEP test of UM including TOP1MT on $SF3B1^{MUT}$ and $BAP1^{MUT}$ tumors [4]. Samples were clustered based on mutational and 8q status. No $BAP1^{MUT}$ tumors had normal copies of 8q.

76 References

- 1. Jager, M.J., et al., Uveal melanoma. Nat Rev Dis Primers, 2020. 6(1): p. 24.
- van den Bosch, T., et al., *Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis*. Invest Ophthalmol Vis
 Sci, 2012. 53(6): p. 2668-74.
- Yavuzyigitoglu, S., et al., *Correlation of Gene Mutation Status with Copy Number Profile in Uveal Melanoma*. Ophthalmology, 2017. **124**(4): p. 573-575.
- Barek, W., et al., Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal
 Melanoma. Cancers (Basel), 2022. 14(3).
- 85 5. Robertson, A.G., et al., *Integrative Analysis Identifies Four Molecular and Clinical Subsets in*86 Uveal Melanoma. Cancer Cell, 2017. 32(2): p. 204-220 e15.
- 87 6. Cassoux, N., et al., Genome-wide profiling is a clinically relevant and affordable prognostic
 88 test in posterior uveal melanoma. Br J Ophthalmol, 2014. 98(6): p. 769-74.
- 89 7. Wierenga, A.P.A., et al., Chromosome 3 and 8q Aberrations in Uveal Melanoma Show
- 90 *Greater Impact on Survival in Patients with Light Iris versus Dark Iris Color.* Ophthalmology,
- 91 2022. **129**(4): p. 421-430.

92